Comparison of the efficacies of tofacitinib and abatacept in patients with rheumatoid arthritis by propensity score matching and their clinical significance
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000037418
- Lead Sponsor
- The Hirose Clinic of Rheumatology TOF-ABT study Office
- Brief Summary
There was no significant difference in the proportion of patients achieving DAS28-ESR remission between the TOF and ABT groups at week24, while change in DAS28-ESR from baseline to week4 was significantly greater in TOF than in ABT. Analysis of EULAR response at week 24 showed that the proportion of patients who achieved a good EULAR response in TOF group was not affected by number of SE copies, whereas in ABT group it was increased significantly with increasing number of SE copies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who meet contraindications for administration of TOF or ABT 2. Pregnant women, nursing women or patients with hope of pregnancy 3. Inability to give informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method